Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency.

Abstract

Vitamin D deficiency is prevalent among women, including patients with polycystic ovary syndrome (PCOS). Some studies have suggested that vitamin D may have a role in cardiovascular disease (CVD). There is very limited data on the vitamin D effect on CVD risk factors in women with PCOS and vitamin D deficiency. To investigate the effect of cholecalciferol on CVD risk factors in PCOS women with vitamin D deficiency. The study was a randomized, placebo-controlled, double blinded trial. Fifty PCOS women with vitamin D deficiency (vitamin D, no. = 24; placebo, no. = 26) aged 20-40 yr, were randomly assigned to receive 3 oral capsules of 50,000 IU vitamin D3 or a placebo (one capsule every 20 days) for two months. Serum vitamin D, PTH, lipid profile, apolipoprotein AI (APO-AI), and high sensitive C- reactive protein (hs-CRP) were measured at baseline and after treatment. Vitamin D3 therapy in PCOS patients, increased serum vitamin D (7.00 ± 2.80 to 22.9 ± 6.14 ng/ml), decreased serum total cholesterol (196.6 ± 32.8 to 179.1 ± 34.1 mg/dl), triglyceride (156.8 ± 73.0 to 130.5 ± 56.5 mg/dl), and VLDL (31.4 ± 14.6 to 26.1 ± 11.3 mg/dl) levels significantly (p < 0.05), but it did not affect serum HDL-cholesterol, LDL-cholesterol, APO-AI, and hs-CRP concentrations. There was no change in variables in the placebo group. Our study showed that vitamin D3 therapy had beneficial effects on some CVD risk factors in PCOS patients with vitamin D deficiency. The trial was registered at IRCT.ir (IRCT138904113140N2).